Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM): novel biological insights and development of early treatment strategies

Impact of optimal follow-up of monoclonal gammopathy of undetermined significance on early diagnosis and prevention of myeloma-related complications

(2010) G. Bianchi et al.   BLOOD

Smoldering (Asymptomatic) Multiple Myeloma: Revisiting the Clinical Dilemma and Looking Into the Future

(2010) Adam J. Waxman et al.   Clinical Lymphoma Myeloma & Leukemia

Initial versus deferred melphalan-prednisone therapy for asymptomatic multiple myeloma stage I - A randomized study

(2010) Martin Hjorth et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Bone marrow microenvironment in myelomagenesis: its potential role in early diagnosis

(2010) Arun Balakumaran et al.   EXPERT REVIEW OF MOLECULAR DIAGNOSTICS

Multiple Myeloma Precursor Disease

(2010) Ola Landgren et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Prognostic Significance of Focal Lesions in Whole-Body Magnetic Resonance Imaging in Patients With Asymptomatic Multiple Myeloma

(2010) Jens Hillengass et al.   JOURNAL OF CLINICAL ONCOLOGY

Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study

(2010) Angela Dispenzieri et al.   LANCET

Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management

(2010) R A Kyle et al.   LEUKEMIA

Molecular and biologic markers of progression in monoclonal gammopathy of undetermined significance to multiple myeloma

(2010) Sham Mailankody et al.   LEUKEMIA & LYMPHOMA

Advances in the Diagnosis, Classification, Risk Stratification, and Management of Monoclonal Gammopathy of Undetermined Significance: Implications for Recategorizing Disease Entities in the Presence of Evolving Scientific Evidence

(2010) S. Vincent Rajkumar et al.   MAYO CLINIC PROCEEDINGS

Pesticide exposure and risk of monoclonal gammopathy of undetermined significance in the Agricultural Health Study

(2009) O. Landgren et al.   BLOOD

A monoclonal gammopathy precedes multiple myeloma in most patients

(2009) B. M. Weiss et al.   BLOOD

Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study

(2009) O. Landgren et al.   BLOOD

Increased risk of monoclonal gammopathy in first-degree relatives of patients with multiple myeloma or monoclonal gammopathy of undetermined significance

(2009) C. M. Vachon et al.   BLOOD

Dynamic Contrast-Enhanced Magnetic Resonance Imaging Identifies a Subgroup of Patients with Asymptomatic Monoclonal Plasma Cell Disease and Pathologic Microcirculation

(2009) J. Hillengass et al.   CLINICAL CANCER RESEARCH

The Potential Role of Curcumin in Patients with Monoclonal Gammopathy of Undefined Significance--Its Effect on Paraproteinemia and the Urinary N-Telopeptide of Type I Collagen Bone Turnover Marker

(2009) T. Golombick et al.   CLINICAL CANCER RESEARCH

Timing of acquisition of deletion 13 in plasma cell dyscrasias is dependent on genetic context

(2009) L. Chiecchio et al.   HAEMATOLOGICA

Loss of 1p and rearrangement of MYC are associated with progression of smouldering myeloma to myeloma: sequential analysis of a single case

(2009) L. Chiecchio et al.   HAEMATOLOGICA

Genetic and immune-related factors in the pathogenesis of lymphoproliferative and plasma cell malignancies

(2009) S. Y. Kristinsson et al.   HAEMATOLOGICA

International Myeloma Working Group molecular classification of multiple myeloma: spotlight review

(2009) R Fonseca et al.   LEUKEMIA

International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma

(2009) M Dimopoulos et al.   LEUKEMIA

Induction of a Chronic Disease State in Patients With Smoldering or Indolent Multiple Myeloma by Targeting Interleukin 1β-Induced Interleukin 6 Production and the Myeloma Proliferative Component

(2009) John A. Lust et al.   MAYO CLINIC PROCEEDINGS

Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease

(2008) B. Barlogie et al.   BLOOD

A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma

(2008) Pellegrino Musto et al.   CANCER

AID-Dependent Activation of a MYC Transgene Induces Multiple Myeloma in a Conditional Mouse Model of Post-Germinal Center Malignancies

(2008) Marta Chesi et al.   CANCER CELL

Clinical and biological significance of RAS mutations in multiple myeloma

(2008) W J Chng et al.   LEUKEMIA

MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis

(2008) F. Pichiorri et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma

(2007) A. Dispenzieri et al.   BLOOD